Quantcast

Industry news that matters to you.  Learn more

Bristol-Myers Squibb and GeneCentric Diagnostics Announce Exploratory Biomarker Research Collaboration

Bristol-Myers Squibb Company (NYSE:BMY) and GeneCentric Diagnostics, Inc. recently announced a biomarker research collaboration to explore whether the application of GeneCentric’s Cancer Subtype Platform (CSP™) might be able to identify translational biomarkers for Opdivo (nivolumab), which may help inform future clinical trials. Additionally, GeneCentric announced it has secured equity funding from Bristol-Myers Squibb that will support the clinical development of GeneCentric’s CSP™ and build-out of GeneCentric’s new laboratory in Research Triangle Park.

LabCorp to Offer New PD-L1 Test for Bristol-Myers Squibb’s OPDIVO Following Collaboration in Clinical Trial

Laboratory Corporation of America [®] Holdings (LabCorp [®] ) (NYSE: LH) recently announced the nationwide availability of a new FDA-approved diagnostic test for PD-L1 associated with the expanded approval of Bristol-Myers Squibb Company’s (BMS) OPDIVO [®] (nivolumab) for the treatment of all appropriate patients with previously-treated non-small cell lung cancer (NSCLC). The PD-L1 IHC 28-8 pharmDx assay was developed by Dako, an Agilent Technologies company. The assay was used to assess PD-L1 expression in the Phase 3 CheckMate 057 trial, in which OPDIVO demonstrated superior overall survival compared to chemotherapy in patients with previously treated metastatic non-squamous NSCLC. This approval expands the indication for OPDIVO to include previously treated non-squamous NSCLC in addition to the squamous NSCLC indication. The test, although not required for OPDIVO, is a new tool that provides physicians with information on the potential survival benefit of treatment with OPDIVO.